Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome

ESC European Society of Cardiology

European Journal of Preventive Cardiology (2022) **29**, 1074–1080
https://doi.org/10.1093/eurjpc/zwab191

FULL RESEARCH PAPER
Cardiac Rehabilitation

Exercise-based cardiac rehabilitation vs. percutaneous coronary intervention for chronic coronary syndrome: impact on morbidity and mortality

Benjamin J.R. Buckley[1,2,*†], Iris A. de Koning [3†], Stephanie L. Harrison[1,2], Elnara Fazio-Eynullayeva[4], Paula Underhill[5], Hareld M.C. Kemps[6,7], Gregory Y.H. Lip [1,2,8,9‡], and Dick H.J. Thijssen[3,8‡]

[1]Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, William Henry Duncan Building, Liverpool L7 8TX, UK; [2]Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK; [3]Department of Physiology, Research Institute for Health Science, Radboud University Medical Centrum, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands; [4]TriNetX Inc., 125 Cambridgepark Drive, Suite 500 Cambridge, MA 02140, USA; [5]TriNetX Inc., London, England EC3V 4AB, GB, UK; [6]Department of Cardiology, Máxima Medical Centre, Veldhoven, Dominee Theodor Fliednerstraat 1, 5631 BM Eindhoven, The Netherlands; [7]Department of Industrial Design, Eindhoven University of Technology, Dominee Theodor Fliednerstraat 1, 5631, Eindhoven, The Netherlands; [8]Liverpool Centre for Cardiovascular Science, Liverpool John Moores University, Liverpool L3 3AF, UK; and [9]Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Søndre Skovvej 15, Forskningens Hus 9000, Aalborg, Denmark

Received 4 August 2021; revised 28 September 2021; editorial decision 27 October 2021; accepted 29 October 2021; online publish-ahead-of-print 11 November 2021

Aims Accumulating evidence questions the clinical value of percutaneous coronary intervention (PCI) for patients with chronic coronary syndrome (CCS). We therefore compare the impact of exercise-based cardiac rehabilitation (CR) vs. PCI in patients with CCS on 18-month mortality and morbidity, and evaluate the effects of combining PCI with exercise-based CR.

Methods and results A retrospective cohort study was conducted in March 2021. An online, real-world dataset of CCS patients was acquired, utilizing TriNetX, a global federated health research network. Patients with CCS who received PCI were first compared with patients who were prescribed exercise-based CR. Second, we compared patients who received both CR + PCI vs. CR alone. For both comparisons, patients were propensity-score matched by age, sex, race, comorbidities, medications, and procedures. We ascertained 18-month incidence of all-cause mortality, rehospitalization, and cardiovascular comorbidity [stroke, acute myocardial infarction (AMI), and new-onset heart failure]. The initial cohort consisted of 18 383 CCS patients. Following propensity score matching, exercise-based CR was associated with significantly lower odds of all-cause mortality [0.37 (95% confidence interval (CI): 0.29–0.47)], rehospitalization [0.29 (95% CI: 0.27–0.32)], and cardiovascular morbidities, compared to PCI. Subsequently, patients that received both CR + PCI did not have significantly different odds for all-cause mortality [1.00 (95% CI: 0.63–1.60)], rehospitalization [1.00 (95% CI: 0.82–1.23)], AMI [1.11 (95% CI: 0.68–1.81)], and stroke [0.71 (95% CI: 0.39–1.31)], compared to CR only.

Conclusions Compared to PCI, exercise-based CR associated with significantly lower odds of 18-month all-cause mortality, rehospitalization, and cardiovascular morbidity in patients with CCS, whilst combining PCI and exercise-based CR associated with lower incident heart failure only.

Keywords Chronic coronary syndrome • Angina • Cardiac rehabilitation • Exercise • Percutaneous coronary intervention • Secondary prevention

* Corresponding author. Tel: +44 (0)151 794 2000, Email: benjamin.buckley@liverpool.ac.uk
† The first two authors contributed equally as first author.
‡ The last two authors are joint senior authors.

Introduction

Coronary artery disease is highly common in the Western population,[1] with chronic coronary syndrome (CCS) being a major public health concern.[2] Patients with CCS receive optimal medical treatment, usually followed by percutaneous coronary intervention (PCI) to target the stenotic coronary artery. Accumulating evidence questions the clinical value of PCI for reducing mortality and cardiovascular events in patients with CCS,[3–7] especially in the short-term (1–2 years following PCI). This highlights the need to explore alternative treatment strategies for patients with CCS.

Physical inactivity plays a crucial role in the development and progression of cardiovascular disease, including CCS.[8] Previous work revealed that exercise-based cardiac rehabilitation (CR) increases exercise capacity, improves quality of life, and reduces morbidity and mortality in patients with cardiovascular disease.[9,10] Such benefits may also apply to patients with CCS. Indeed, exercise-based CR following PCI is associated with improved event-free survival, and lower mortality compared to PCI alone.[11] Previous randomized controlled trials (RCTs) in patients with CCS suggested that exercise-based CR is associated with improved coronary collateral flow index, improved exercise capacity, and superior 1-year survival rates compared to PCI.[12,13] In line with these findings, a recent Cochrane systematic review found a small increase in exercise capacity following CR, as compared to standard treatment, though it was highlighted that further research was needed to determine the impact on mortality and morbidity.[14] Nevertheless, exercise-based CR is not currently part of routine care for patients with CCS, either as a first choice option (i.e. instead of PCI) or in addition to PCI.[15,16]

The first aim of this study was to examine the association between exercise-based CR and 18-month all-cause mortality, rehospitalization, and cardiovascular morbidity vs. PCI alone in patients diagnosed with CCS. Second, we assessed the added value of combining exercise-based CR with PCI, compared to exercise-based CR alone, on these clinical outcome parameters. We hypothesized that exercise-based CR is associated with lower clinical event rates and cardiovascular morbidity in patients with CCS, compared to PCI. Further, we hypothesized there would be no added value of combining PCI to exercise-based CR.

Methods

Study design and participants

A retrospective observational study was conducted using anonymized data within TriNetX, a global federated health research network with access to electronical medical records (EMRs) from participating healthcare organizations including academic medical centres, specialty physician practices, and community hospitals, predominantly in the USA.[17] Chronic coronary syndrome was identified from International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM, ICD-10-CM) codes in patient EMRs: I20 (angina pectoris), excluding I20.0 (unstable angina pectoris). Cardiac rehabilitation was identified from ICD-10-CM codes Z71.82 (exercise counselling), Healthcare Common Procedure Coding System (HCPCS) codes G0422 (intensive CR; with or without continuous ECG), S9472 (CR programme, non-physician provider, per diem), or Current Procedural Terminology (CPT) codes 93797/93798 (physician or other qualified healthcare professional services for outpatient CR with/without ECG) and 1013171 (physician or other qualified health care professional services for outpatient CR). Percutaneous coronary intervention was identified from ICD-10-CM codes 92928 [percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch] and 92941 [percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction (AMI), coronary artery, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy, angioplasty, including aspiration thrombectomy when performed, single vessel] and HCPCS codes C1725 [catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)] and C600 [percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch]. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[18] As a federated network, research studies using the TriNetX research network do not require ethical approvals as no patient identifiable identification is received.

Data collection

The TriNetX network was searched on 29 March 2021 and an online real-world dataset of patients with CCS was acquired.[17] All cohorts were aged ≥18 years with exercise-based CR and/or PCI recorded in EMRs within 6 months of an CCS diagnosis. For both the exercise-based CR and PCI cohorts, patients with CCS were identified in EMRs from at least 18 months prior to the search date to ensure a minimum follow-up of 18 months from CCS diagnosis (or 12 months from CR/PCI). At the time of the search, 45 participating healthcare organizations had data available for patients who met the study inclusion criteria.

Statistical analysis

All statistical analyses were completed on the TriNetX online platform. Baseline characteristics were compared using χ^2 tests for categorical variables and independent-sample *t*-tests for continuous variables. Current exercise-based CR provision is typically reserved for cardiovascular patients following an acute coronary syndrome, heart failure (HF), or those undergoing a revascularization procedure (coronary artery bypass graft or planned PCI). Thus, propensity score matching (PSM) was used to control for these differences in the two cohorts. The exercise-based CR and PCI cohorts were 1:1 PSM using logistic regression for age at CCS diagnosis, sex, race, hypertensive diseases, ischaemic heart diseases, cerebrovascular diseases, diabetes mellitus, chronic kidney disease, HF, cardiovascular procedures (e.g. cardiography, echocardiography, cardiac catheterization, cardiac devices, electrophysiological procedures), and cardiovascular medications (e.g. beta-blockers, antiarrhythmics, diuretics, antilipaemic agents, antianginals, calcium channel blockers, angiotensin-converting enzyme inhibitors). These variables were chosen because they are established cardiovascular disease risk factors and/or were significantly different between the two cohorts. The TriNetX platform uses 'greedy nearest-neighbour matching' with a calliper of 0.1 pooled standard deviations. Following PSM, logistic regressions produced odds ratios (ORs) with 95% confidence intervals (CIs) for 18-month incidence of all-cause mortality, rehospitalization, stroke, AMI, and new-onset HF. These outcomes were first compared between exercise-based CR and PCI and

second between exercise-based CR and CR + PCI. Statistical significance was set at $P < 0.05$.

Results

The initial cohort consisted of 18 383 patients with CCS with at least 18-month follow-up. Of this study population, 12 676 patients had a history of PCI treatment alone, 4368 patients received exercise-based CR within 6 months following CCS diagnosis, and 1339 patients had a history of CR + PCI following CCS diagnosis (*Table 1*). The cohort of CCS patients that received exercise-based CR only were younger, had a lower proportion of white ethnicity, a higher proportion of unknown ethnicity, and had higher proportions of health conditions, cardiovascular procedures, and medications than the PCI group (*Table 1*). Although some variables were *significantly* different between the cohorts (White and Asian ethnicity and cardiovascular medications) following PSM, the cohorts were considered well-matched with small absolute diffences between cohorts (*Table 1*). For our second research question, the CR + PCI cohort had more people identified as white ethnicity, less people identified as unknown ethnicity, less patients with HF and cerebrovascular diseases, and more patients with ischaemic heart disease, cardiovascular procedures, and medications compared to the CR group. Following 1:1 PSM, the two groups of $n = 1337$ showed no statistically different characteristics (*Table 2*).

Cardiac rehabilitation vs. percutaneous coronary intervention: mortality, rehospitalization, and morbidity

After PSM, 18-month mortality was 2.0% in CCS patients receiving CR ($n = 86$, of 4346 patients) and 5.2% in patients undergoing PCI ($n = 225$, of 4327 patients, $P < 0.0001$), resulting in 63% lower odds of all-cause mortality in the CR cohort (OR 0.37, 95% CI: 0.29–0.47) compared to PCI. Rehospitalization rate was significantly lower in CCS patients receiving CR (16.5%, $n = 717$ of 4357 patients) compared to PCI (40.2%, $n = 1751$ of 4357 patients, $P < 0.0001$). Logistic regression models showed 71% lower odds of rehospitalization (OR 0.29, 95% CI: 0.27–0.32) after CR compared to PCI. The CR cohort also showed significantly lower odds for morbidity compared to PCI only: AMI (OR 0.72, 95% CI: 0.57–0.90) and stroke (OR 0.58, 95% CI: 0.43–0.79). Cardiac rehabilitation was not significantly associated with lower odds of new onset HF (OR 0.88, 95% CI: 0.74–1.05) (*Figure 1*).

Cardiac rehabilitation + percutaneous coronary intervention vs. cardiac rehabilitation: mortality, rehospitalization, and morbidity

A 18-month mortality was 2.7% in the CR + PCI cohort ($n = 36$ of 1334 patients) and 2.7% in the CR cohort ($n = 36$ of 1332 patients,

Table 1 Patient Characteristics % (*n*) of the chronic coronary syndrome populations with percutaneous coronary intervention only or with cardiac rehabilitation only, before and after propensity score matching

	Initial populations			Propensity-score matched populations		
	CCS with PCI only ($n = 12\,676$)	CCS with CR only ($n = 4368$)	*P*-value	CCS with PCI only ($n = 4357$)	CCS with CR only ($n = 4357$)	*P*-value
Age (years) at diagnoses; mean (SD)	65.3 (11.4)	64.2 (11.6)	<0.0001	64.7 (11.1)	64.2 (11.6)	0.06
Sex						
Male	68.3 (8656)	66.9 (2924)	0.1004	66.6 (2903)	67.0 (2918)	0.73
Female	31.7 (4019)	33.1 (1444)	0.0984	33.3 (1453)	33.0 (1439)	0.75
Ethnicity[a]						
White	82.5 (10 460)	77.6 (3388)	<0.0001	80.3 (3498)	77.8 (3388)	0.004
Black or African	10.5 (1325)	11.2 (491)	0.1455	10.3 (450)	11.3 (491)	0.16
Asian	1.5 (193)	1.8 (80)	0.1607	1.3 (57)	1.8 (80)	0.047
Unknown	5.1 (647)	9.2 (400)	<0.0001	8.0 (350)	8.9 (389)	0.13
Ischaemic heart diseases	84.1 (10 658)	96.7 (4222)	<0.0001	96.9 (4220)	96.6 (4211)	0.59
Hypertensive diseases	68.2 (8643)	78.1 (3413)	<0.0001	79.6 (3469)	78.1 (3402)	0.08
Diabetes mellitus	32.6 (4134)	35.9 (1566)	<0.0001	36.3 (1580)	35.9 (1565)	0.74
Heart failure	19.0 (2408)	27.2 (1190)	<0.0001	26.1 (1137)	27.1 (1182)	0.28
Cerebrovascular diseases	12.8 (1622)	16.9 (738)	<0.0001	16.8 (734)	16.8 (733)	0.98
Chronic kidney disease	14.6 (1853)	14.9 (651)	0.6456	14.3 (624)	14.9 (651)	0.41
Cardiovascular procedures[b]	77.4 (9806)	89.1 (3891)	<0.0001	88.7 (3865)	89.1 (3880)	0.61
Cardiovascular medications[c]	74.0 (9380)	85.2 (3720)	<0.0001	88.2 (3842)	85.1 (3709)	<0.0001

Values are % (*n*) unless otherwise stated.
Baseline characteristics were compared using a χ^2 test for categorical variables and an independent-sample *t*-test for continuous variables.
[a]Data are taken from structured fields in the electronic medical record systems of the participating healthcare organizations, therefore, there may be regional or country-specific differences in how race categories are defined.
[b]Cardiovascular procedures include cardiography, echocardiography, catheterization, cardiac devices, and electrophysiological procedures.
[c]Cardiovascular medications include beta-blockers, antiarrhythmics, diuretics, lipid lowering agents, antianginals, calcium channel blockers, and ACE inhibitors.

Table 2 Patient characteristics % (*n*) of the chronic coronary syndrome populations with cardiac rehabilitation only or with both cardiac rehabilitation and percutaneous coronary intervention, before and after propensity score matching

	Initial populations			Propensity-score matched populations		
	CCS with CR only (*n* = 4368)	CCS with CR + PCI (*n* = 1339)	*P*-value	CCS with CR only (*n* = 1337)	CCS with CR + PCI (*n* = 1337)	*P*-value
Age (years) at diagnoses; mean (SD)	64.2 (11.6)	65.3 (11.1)	0.0023	65.2 (11.1)	65.3 (11.1)	0.77
Sex						
Male	66.9 (2924)	71.0 (951)	0.0051	71.7 (958)	71.0 (949)	0.70
Female	33.1 (1444)	29.0 (388)	0.0051	28.3 (379)	29.0 (388)	0.70
Ethnicity[a]						
White	77.6 (3388)	83.3 (1116)	<0.0001	84.9 (1135)	83.4 (1115)	0.29
Black or African	11.2 (491)	10.4 (139)	0.3797	8.5 (114)	10.4 (139)	0.10
Asian	1.8 (80)	1.7 (23)	0.7843	1.7 (23)	1.7 (23)	1.00
Unknown	9.2 (400)	4.3 (57)	<0.0001	4.8 (64)	4.3 (57)	0.51
Ischaemic heart diseases	96.7 (4222)	99.8 (1336)	<0.0001	99.9 (1335)	99.8 (1334)	0.65
Hypertensive diseases	78.1 (3413)	79.5 (1064)	0.3020	80.0 (1070)	79.5 (1063)	0.74
Diabetes mellitus	35.9 (1566)	35.5 (476)	0.8398	35.7 (477)	35.6 (476)	0.97
Heart failure	27.2 (1190)	21.1 (282)	<0.0001	20.1 (269)	21.1 (282)	0.53
Cerebrovascular diseases	16.9 (738)	12.2 (164)	<0.0001	12.0 (161)	12.3 (164)	0.86
Chronic kidney disease	14.9 (651)	13.6 (182)	0.2343	12.8 (171)	13.6 (182)	0.53
Cardiovascular procedures[b]	89.1 (3891)	98.4 (1317)	<0.0001	98.5 (1317)	98.4 (1315)	0.76
Cardiovascular medications[c]	85.2 (3720)	94.5 (1266)	<0.0001	94.1 (1258)	94.5 (1264)	0.62

Values are % (*n*) unless otherwise stated.
Baseline characteristics were compared using a χ^2 test for categorical variables and an independent-sample *t*-test for continuous variables.
[a]Data are taken from structured fields in the electronic medical record systems of the participating healthcare organizations, therefore, there may be regional or country-specific differences in how race categories are defined.
[b]Cardiovascular procedures include cardiography, echocardiography, catheterization, cardiac devices, and electrophysiological procedures.
[c]Cardiovascular medications include beta-blockers, antiarrhythmics, diuretics, lipid lowering agents, antianginals, calcium channel blockers, and ACE inhibitors.



Figure 1 Odds of all-cause mortality, rehospitalization, and morbidity in patients receiving cardiac rehabilitation vs. percutaneous coronary intervention. All-cause mortality, rehospitalization, and cardiovascular morbidities at 18-month follow-up from chronic coronary syndrome diagnosis; comparing chronic coronary syndrome patients who received cardiac rehabilitation (*n* = 4357) to chronic coronary syndrome patients who received percutaneous coronary intervention (*n* = 4357). CI, confidence interval; CR, cardiac rehabilitation; *n*, number of patients; PCI, percutaneous coronary intervention.

	18-month events, n (%)				
	CR cohort	CR+PCI cohort	Odds Ratio	95% CI	*p*-value
All-cause mortality	36/1,332 (2.7%)	36/1,334 (2.7%)	1.00	0.63-1.60	0.9949
Rehospitalisation	224/1,337 (16.8)	224/1,337 (16.8)	1.00	0.82-1.23	1.0000
Cardiovascular morbidities					
Acute myocardial infarction	35/907 (3.9%)	31/886 (3.5%)	1.11	0.68-1.81	0.6857
Stroke	18/1,288 (1.4%)	25/1,277 (2.0%)	0.71	0.39-1.31	0.2692
Heart failure	95/1,036 (9.2%)	61/1,034 (5.9%)	1.61	1.15-2.25	0.0048



Figure 2 Odds of all-cause mortality, rehospitalization, and morbidity in patients receiving cardiac rehabilitation only vs. cardiac rehabilitation and percutaneous coronary intervention combined. All-cause mortality, rehospitalization, and cardiovascular morbidities at 18-month follow-up from chronic coronary syndrome diagnosis; comparing chronic coronary syndrome patients who received cardiac rehabilitation only ($n = 1337$) to chronic coronary syndrome patients who received both cardiac rehabilitation and percutaneous coronary intervention ($n = 1337$). CI, confidence interval; CR, cardiac rehabilitation; *n*, number of patients; PCI, percutaneous coronary intervention.

$P = 0.995$). There was no significant difference in odds for all-cause mortality between CR + PCI and CR alone (OR 1.00, 95% CI: 0.63–1.60). The CR + PCI cohort revealed no significant differences in 18-month rehospitalization (16.8%, $n = 224$ of 1337 patients) compared to CR alone (16.8%, $n = 224$ of 1337 patients). Logistic regression models showed no differences in odds for rehospitalization between the two groups (OR 1.00, 95% CI: 0.82–1.23). The CR + PCI cohort showed no significant differences for 18-month occurrence of AMI (OR 1.11, 95% CI: 0.68–1.81) and stroke (OR 0.71, 95% CI: 0.39–1.31), compared to CR alone. The CR cohort showed significantly higher odds for new onset of HF compared to CR + PCI (OR 1.61, 95% CI: 1.15–2.25) (*Figure 2*).

Discussion

The aim of this study was to evaluate the potential role of exercise-based CR in patients with CCS, either compared to PCI alone or in addition to PCI. First, we found that prescription of exercise-based CR for patients with CCS, compared to traditional referral for PCI, was associated with significantly lower odds for all-cause mortality, rehospitalization and cardiovascular morbidity at 18 months from diagnosis. Second, when compared to CR alone, CCS patients who received PCI *in addition* to exercise-based CR associated with lower incident heart failure, only. The addition of PCI to exercise-based CR did not seem to alter the benefits of exercise-based CR on all-cause mortality, rehospitalization, AMI, or stroke in patients with CCS. These observations highlight the potential for exercise-based CR to play a central role in management of patients with CCS, which associates with improved clinical outcomes compared to current, invasive strategies such as PCI.

Given the large sample size, long-term follow-up, and PSM cohorts, this study provides promising evidence that exercise-based CR is associated with superior clinical outcomes at 18 months compared to PCI alone. In the past decade, several studies have explored the clinical treatment of patients with CCS. Recently, both the COURAGE trial and the ISCHEMIA trial revealed limited impact of routine invasive strategy, when added to optimal medical treatment, in patients with CCS on the 4-year risk for ischaemic cardiovascular events or all-cause mortality.[6,7] Indeed, the 1-year analyses revealed a significantly higher event rate in CCS patients who underwent the routine invasive strategy compared to optimal medical treatment.[6] When comparing the 1-year post-PCI mortality rates from previous work (1–4%),[19,20] including the ISCHEMIA trial (1.7%),[21] we observed a somewhat higher mortality rate (5%), perhaps explained by the design of these previous studies, which excluded high-risk patients and comorbidity, subsequently underestimating the mortality rate in the real-world population of patients with CCS. Indeed, recent studies focussing on a real-world population report relatively high mortality rates (11.3%, 4.7 years follow-up),[11] supporting supporting the real-world representation of our data. More importantly, our data reinforces the observations of the ISCHEMIA trial pertaining to the short-term effects of invasive strategies in patients with CCS and the high risk for mortality and morbidity following PCI.

The results of the current study suggest that exercise-based CR is associated with significantly lower odds for all-cause mortality, rehospitalization, and cardiovascular morbidity, compared to matched patients who received PCI. These observations are in line with a previous, small-sized RCT ($n = 101$).[12] in which the effects of exercise-based CR were compared against PCI in patients with CCS across 1-year follow-up. Hambrecht *et al.* showed improved exercise capacity and superior event-free survival in CCS patients who received exercise-based CR, despite no observed changes to the coronary artery stenosis. In a recent Cochrane systematic review and meta-analysis (seven trials with $n = 581$ CCS patients), it was deemed that CR conveyed a small improvement in exercise capacity for patients with CCS, though further research was needed to determine the

impact on mortality and morbidity.[14] Another study showed that exercise-based CR improved myocardial perfusion through collateralization and enhanced coronary endothelial function in CCS patients.[13] These direct effects of exercise-based CR on coronary artery function and structure may explain the significantly lower 1-year event rate observed by these authors.[22,23] To our knowledge, our PSM-based comparison between patients with CCS who underwent either exercise-based CR ($n = 4368$) *or* PCI ($n = 12\,676$), represents the first large-scale, real-world evidence reinforcing the observations from Hambrecht *et al*. This highlights the need to further explore the clinical impact of exercise-based CR in patients with CCS, adopting prospective research powered to investigate the effects on long-term clinical outcomes (in addition to patient reported outcomes, such as quality of life).

Despite the observations from the COURAGE and ISCHEMIA trials and the absence of a reliable evidence base, invasive procedures have become routine care in cardiology for patients with CCS. Accordingly, our study explored the association of prescription to PCI in addition to exercise-based CR compared to exercise-based CR alone (i.e. PCI+CR vs. CR). A first, somewhat surprising observation, was that only ~1 in 10 patients that underwent PCI were prescribed additional exercise-based CR (1339 vs. 12 676, respectively). This clearly demonstrates that exercise-based CR is not routinely prescribed following PCI. Subsequently, we evaluated the potential benefits of combining exercise-based CR with PCI, but found that this combination of therapeutic strategies does not outperform the clinical benefits of exercise-based CR alone. Since groups were well matched for important cardiovascular risk factors, our observations support the relevance of prescribing exercise-based CR in real-world CCS populations, with exercise-based CR being associated with providing systemic benefit to the entire arterial system.[9,10,12,13] Combining PCI with exercise-based CR did however demonstrate a significantly lower proportion of new-onset heart failure (and may therefore be an interesting line of inquiry in CCS patients at high-risk of developing heart failure). Nonetheless, this did not translate to differences in odds between both therapeutics for all-cause mortality, rehospitalization, stroke, or AMI. Although PCI improves coronary perfusion allowing increased cardiac output,[6,12] these benefits may not outweigh the potential risks of PCI for patients with CCS as found in the ISCHEMIA trial.[6]

Limitations

Several limitations must be acknowledged. Although our study is based on a comprehensive database of EMRs from multiple healthcare organizations, some comorbidities may be under-reported, and details of certain characteristics were not available. Important information that is unavailable from EMRs include the type of exercise incorporated in the CR programmes (i.e. frequency, intensity, type, duration), intervention adherence, and type/intensity of medical support. Other important under-reported variables include coronary status and baseline status of CCS, which is important as it prevented insight into the impact of disease severity. Therefore, we cannot exclude the presence of selection bias for the CR vs. PCI cohort comparisons. This is important to consider when interpreting these results. Similarly, we could not control for some potential confounding (e.g. left ventricular function, the extent of myocardial ischaemia, lifestyle and socioeconomic status), and we were unable to fully control for ethnicity. Whilst this difference in ethnicity cannot be ignored, the small difference unlikely explains our primary finding. In addition, medication use was lower in the exercise-based CR group compared to the PCI group, which is in agreement with a recent study.[11] At least, given the established cardioprotective effects of these drugs the lower medication use unlikely explains all of the lower mortality and morbidity in the exercise-based CR group. These limitations highlight the need for subsequent prospective trials to confirm the findings suggested in the present study.

Conclusions

In conclusion, the present study was designed to evaluate the potential role of exercise-based CR in CCS patients, and the added value of PCI for exercise-based CR, compared to exercise-based CR alone. Exercise-based CR was associated with a significantly lower odds of 18-month all-cause mortality, rehospitalization, and cardiovascular morbidity in CCS patients, whilst *addition* of PCI improved heart failure outcomes only. This suggests that exercise-based CR is a promising alternative treatment strategy for patients with CCS, and warrants prospective investigation.

Conflict of interest: B.J.R.B. has received funding from Bristol-Myers Squibb (BMS)/Pfizer. S.L.H. has received funding from BMS. E.F.-E. and P.U. are employees of TriNetX LLC. G.Y.H.L.: consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

Data availability

To gain access to the data in the TriNetX research network, a request can be made to TriNetX (https://live.trinetx.com), but costs may be incurred, a data sharing agreement would be necessary, and no patient identifiable information can be obtained.

References

1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW; On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation* 2021;**143**:CIR0000000000000950.
2. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. *Circulation* 2018;**137**:e67–e492.

3. Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. *JAMA Intern Med* 2014;**174**:232–240.
4. Al-Lamee R, Thompson D, Dehbi H-M, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet* 2018;**391**:31–40.
5. Hochman JS, Reynolds HR. International study of comparative health effectiveness with medical and invasive approaches: primary report of clinical outcomes. *Circulation* 2019;**140**:E1004.
6. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, Lopez-Sendon J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 2020;**382**:1395–1407.
7. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;**356**:1503–1516.
8. Lahtinen M, Toukola T, Junttila MJ, Piira OP, Lepojarvi S, Kaariainen M, Huikuri HV, Tulppo MP, Kiviniemi AM. Effect of changes in physical activity on risk for cardiac death in patients with coronary artery disease. *Am J Cardiol* 2018;**121**:143–148.
9. de Vries H, Kemps HM, van Engen-Verheul MM, Kraaijenhagen RA, Peek N. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. *Eur Heart J* 2015;**36**:1519–1528.
10. Kotseva K, Wood D, De Bacquer D; EUROASPIRE investigators. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. *Eur J Prev Cardiol* 2018;**25**:1242–1251.
11. Eijsvogels TMH, Maessen MFH, Bakker EA, Meindersma EP, van Gorp N, Pijnenburg N, Thompson PD, Hopman MTE. Association of cardiac rehabilitation with all-cause mortality among patients with cardiovascular disease in the Netherlands. *JAMA Netw Open* 2020;**3**:e2011686.
12. Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler G. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation* 2004;**109**:1371–1378.
13. Mobius-Winkler S, Uhlemann M, Adams V, Sandri M, Erbs S, Lenk K, Mangner N, Mueller U, Adam J, Grunze M, Brunner S, Hilberg T, Mende M, Linke AP, Schuler G. Coronary collateral growth induced by physical exercise: results of the impact of intensive exercise training on coronary collateral circulation in patients with stable coronary artery disease (EXCITE) trial. *Circulation* 2016;**133**:1438–1448; discussion 1448.
14. Long L, Anderson L, Dewhirst AM, He J, Bridges C, Gandhi M, Taylor RS. Exercise-based cardiac rehabilitation for adults with stable angina. *Cochrane Database Syst Rev* 2018;**2**:CD012786.
15. van Engen-Verheul M, de Vries H, Kemps H, Kraaijenhagen R, de Keizer N, Peek N. Cardiac rehabilitation uptake and its determinants in the Netherlands. *Eur J Prev Cardiol* 2013;**20**:349–356.
16. Long L, Anderson L, He J, Gandhi M, Dewhirst A, Bridges C, Taylor R. Exercise-based cardiac rehabilitation for stable angina: systematic review and meta-analysis. *Open Heart* 2019;**6**:e000989.
17. TriNetX Platform. https://live.trinetx.com (4 November 2021).
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008;**61**:344–349.
19. Hirsch A, Verouden NJ, Koch KT, Baan J Jr, Henriques JP, Piek JJ, Rohling WJ, van der Schaaf RJ, Tijssen JG, Vis MM, de Winter RJ. Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris. *Am J Cardiol* 2009;**104**:333–337.
20. Natsuaki M, Morimoto T, Yamamoto E, Watanabe H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Hanaoka KI, Tanabe K, Kozuma K, Kimura T; STOPDAPT trial investigators. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. *PLoS One* 2020;**15**:e0227612.
21. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 2020;**382**:1395–1407.
22. Green DJ, Hopman MT, Padilla J, Laughlin MH, Thijssen DH. Vascular adaptation to exercise in humans: role of hemodynamic stimuli. *Physiol Rev* 2017;**97**:495–528.
23. Thijssen DH, Carter SE, Green DJ. Arterial structure and function in vascular ageing: are you as old as your arteries? *J Physiol* 2016;**594**:2275–2284.